Compare BPRN & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BPRN | CERS |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.5M | 276.0M |
| IPO Year | 2022 | 1996 |
| Metric | BPRN | CERS |
|---|---|---|
| Price | $34.84 | $2.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.8K | ★ 3.0M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | ★ 74.84 | 27.27 |
| EPS | ★ 0.91 | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | $9.96 | $19.95 |
| Revenue Next Year | $6.13 | $8.84 |
| P/E Ratio | $38.33 | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $29.21 | $1.15 |
| 52 Week High | $37.99 | $3.15 |
| Indicator | BPRN | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 64.69 |
| Support Level | $34.66 | $1.84 |
| Resistance Level | $36.53 | $2.96 |
| Average True Range (ATR) | 0.70 | 0.18 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 61.93 | 71.30 |
Princeton Bancorp Inc is a full-service financial institution providing personal and business banking services, including checking and savings accounts, as well as a range of lending products such as residential, commercial, construction, and consumer loans, including home equity loans and lines of credit. The Bank operates branches and conducts loan origination activities in areas of the New York City metropolitan area. Its loan portfolio is segmented into commercial real estate (including owner-occupied, non-owner-occupied, and multi-family properties), construction loans (mainly for residential developments), commercial and industrial loans (for business purposes), residential real estate loans (secured by one-to-four family properties), and consumer/HELOC loans.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.